Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic γδT Cells for R/R NHL and PTCL
NCT04696705Phase 1Unknown
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic gamma-delta T cells in non-Hodgkin lymphoma (NHL) and peripheral T-cell lymphoma (PTCL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of Adverse events (AEs) at 2 years, Dose limited toxicity at 28 days and 1 more. Status: unknown.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
non-Hodgkin lymphoma (NHL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04696705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696705.